I still say Medivir is my favorite name due to their position with TMC435 and the nuke now in the clinic, combined with their valuation. That said, they are already tied up with JNJ. (That's not to say JNJ couldn't acquire them at some point.) My second favorite play would be ACHN, as I especially like the fact that they have no partner, so there is the potential for a big name partner, or acquirer, to boost their shares. But, I'm on the sidelines for now as I don't think anything happens with them until at least next year, at least if you believe what ACHN management has been guiding for (wanting to get additional data from their HCV candidates to boost value).
Market Data 
Markets 
AI
